UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000009498 |
|---|---|
| Receipt number | R000011159 |
| Scientific Title | A Phase I/II, open-label, non-randomized, multi-center, dose escalation study of olaparib in combination with eribulin mesylate to assess the safety, tolerability, and efficacy in patients with recurrent or metastatic triple-negative-type breast cancer, who have received anthracycline and taxane agents |
| Date of disclosure of the study information | 2012/12/10 |
| Last modified on | 2018/03/05 11:42:46 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2012/12/06 20:37:58 | ||
| 2 | Update | 2012/12/28 13:16:39 | Institutions |
|
| 3 | Update | 2012/12/28 16:15:58 | Anticipated trial start date |
|
| 4 | Update | 2013/01/23 10:32:03 | UMIN ID1 |
|
| 5 | Update | 2013/01/23 10:38:08 | Recruitment status |
|
| 6 | Update | 2014/06/10 10:52:35 | TEL Last name of contact person Last name of contact person Organization Organization TEL Institutions |
|
| 7 | Update | 2014/06/10 11:00:33 | Key inclusion criteria Key inclusion criteria Key exclusion criteria Target sample size |
|
| 8 | Update | 2014/12/16 17:59:46 | Recruitment status |
|
| 9 | Update | 2016/02/03 10:13:39 | Last follow-up date |
|
| 10 | Update | 2018/03/05 11:42:46 | Recruitment status |
